Preparation of noninfectious scRNAseq samples from SARS-CoV-2-infected epithelial cells

Author:

Osborn Raven M.ORCID,Leach Justin,Zanche Michelle,Ashton John M.,Chu ChinYi,Thakar Juilee,Dewhurst Stephen,Rosenberger Sonia,Pavelka Martin,Pryhuber Gloria S.,Mariani Thomas J.,Anderson Christopher S.ORCID

Abstract

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS coronavirus 2 (SARS-CoV-2) virus. Direct assessment, detection, and quantitative analysis using high throughput methods like single-cell RNA sequencing (scRNAseq) is imperative to understanding the host response to SARS-CoV-2. One barrier to studying SARS-CoV-2 in the laboratory setting is the requirement to process virus-infected cell cultures, and potentially infectious materials derived therefrom, under Biosafety Level 3 (BSL-3) containment. However, there are only 190 BSL3 laboratory facilities registered with the U.S. Federal Select Agent Program, as of 2020, and only a subset of these are outfitted with the equipment needed to perform high-throughput molecular assays. Here, we describe a method for preparing non-hazardous RNA samples from SARS-CoV-2 infected cells, that enables scRNAseq analyses to be conducted safely in a BSL2 facility–thereby making molecular assays of SARS-CoV-2 cells accessible to a much larger community of researchers. Briefly, we infected African green monkey kidney epithelial cells (Vero-E6) with SARS-CoV-2 for 96 hours, trypsin-dissociated the cells, and inactivated them with methanol-acetone in a single-cell suspension. Fixed cells were tested for the presence of infectious SARS-CoV-2 virions using the Tissue Culture Infectious Dose Assay (TCID50), and also tested for viability using flow cytometry. We then tested the dissociation and methanol-acetone inactivation method on primary human lung epithelial cells that had been differentiated on an air-liquid interface. Finally, we performed scRNAseq quality control analysis on the resulting cell populations to evaluate the effects of our virus inactivation and sample preparation protocol on the quality of the cDNA produced. We found that methanol-acetone inactivated SARS-CoV-2, fixed the lung epithelial cells, and could be used to obtain noninfectious, high-quality cDNA libraries. This methodology makes investigating SARS-CoV-2, and related high-containment RNA viruses at a single-cell level more accessible to an expanded community of researchers.

Funder

Burroughs Wellcome Fund

National Center for Advancing Translational Sciences

NHLBI Division of Intramural Research

Technology Development Fund Award, School of Medicine and Dentistry, University of Rochester

Scientific Advisory Committee Incubator Award, School of Medicine and Dentistry, University of Rochester

Health Science Center for Computational Innovation Pilot Award, School of Medicine and Dentistry, University of Rochester

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference24 articles.

1. Mechanisms of SARS-CoV-2 transmission and pathogenesis;AG Harrison;Trends in immunology,2020

2. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus;CR Baskin;Proceedings of the National Academy of Sciences,2009

3. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host &;SA Lowery;Microbe,2021

4. A review of COVID-19 biomarkers and drug targets: resources and tools;FP Caruso;Briefings in Bioinformatics,2021

5. Single-Cell RNAseq Profiling of Human γδ T Lymphocytes in Virus-Related Cancers and COVID-19 Disease.;JP Cerapio;Viruses.,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3